Oral Biolife Inc.’s Post

Discover how Arrow Dx is leading the charge in the battle against fatty liver disease through biotech innovation in our newest blog. Unveil the silent epidemic's nuances and the power of personalized medicine. 🧬🔬 Read the full blog here: https://lnkd.in/edAvAiqc #BiotechInnovation #FattyLiverDisease #HealthcareRevolution

“We understand chronic HBV profoundly impacts the quality of life for people living with the disease, and we are excited to share our ongoing research efforts with the overall goal of working towards a functional cure.” For #HCPs: It’s an important year for #TeamBarinthus at the EASL | The Home of Hepatology 2024 Congress, as we prepare to present two clinical data updates on our lead #hepatitisB asset, VTP-300. These data underscore our commitment to improving outcomes for people with #HepB, providing hope for a potential functional cure. Read more details about our poster and oral sessions here: https://lnkd.in/eVgQrZ8s #EASL2024 #liverdisease #HBV #innovation

Today the EMA rejects #Biogen/#Eisai application for the commercialization of Lecanemab for #Alzheimer's disease in Europe because they argue that the risks overweight the potential benefits. Right or wrong, this decision highlights the desperate need for #precisionmedicine in this field. Acknowledging the biological heterogeneity in AD is the key to unlock patient stratification and reach significant benefits with minimal risk.

In the field of medical diagnostics, #Calprotectin Rapid Diagnostic Test Kits have emerged as a valuable tool for assessing gastrointestinal health through the analysis of feces samples. These kits are designed to detect and quantify Calprotectin, a specific biomarker found in fecal matter, offering significant advantages in early disease detection and monitoring. In this article, we will explore the importance of Calprotectin Rapid Diagnostic Test Kits in feces sample analysis, their applications, and the benefits they bring to healthcare. Full article >> https://lnkd.in/gwU7uWcT

🌟 Revolutionizing Anti-Inflammatory Treatments at Aila Biotech 🌟 At Aila Biotech, we're excited to share our groundbreaking research that could transform how we approach inflammation. Traditional anti-inflammatory drugs treat the entire body, but our latest findings suggest a new possibility: targeting specific areas needing treatment. Imagine shutting down the immune response and repairing damage precisely where it's needed, without affecting the rest of the body. This innovation will allow us to use higher, more targeted doses, leading to faster and more effective treatments. 👉 Join us as we pave the way for more precise and rapid disease treatment solutions for the treatment of neuroinflammation. #AilaBiotech #MedicalInnovation #TargetedTherapy #InflammationResearch #HealthcareRevolution https://lnkd.in/eqKYpXGD

High Endoscopic Cuffitis Rates Post-Ileal Pouch-Anal Anastomosis: Association with Extensive Disease and Biologic Exposure by Posner H, Lombard R (...) Kayal M et 5 al. in Inflamm Bowel Dis

THERE IS NO (easy way of defining) DISEASE MODIFICATION!!! Please have a look at our latest work where we critically appraise the disease modification concept. The concept is quite en vogue especially in non-communicable diseases and intends to allocate „quality labels“ to medical treatments. However, we here argue that the concept is - after all - arbitrary and that „disease modification“ (as well as „therapeutic causality“) cannot be reasonably assessed, let alone, objectified. Rather, there is a continuum of treatment and disease outcomes which is not sufficiently addressed by the disease modification concept. If patients survive in good quality-of-live, no one cares whether a treatment is disease-modifying. Predictive- and monitoring biomarkers are important for treatment optimization and personalization though . #diseasemodification #therapeuticcausality #noncommunicabledisease #biomarker Frank Rassouli Florent Baty Martin Brutsche Kantonsspital St.Gallen KSSG

Maths In Health is excited to share the recent publication of a paper co-authored by MiH partners! This study assesses the cost effectiveness of treatment sequencing for ulcerative colitis (UC) and Crohn’s disease (CD) by leveraging real-world evidence. This research highlights the potential for real-world evidence to reshape cost-effectiveness in treatment strategies for inflammatory bowel diseases. #costeffectiveness #ulcerativecolitis #crohnsdisease #realworldevidence #vedolizumab Check out the full paper here 👇

Rare Disease Day presents an opportunity to highlight significant advancements in #genomicmedicine, recognize the challenges associated with living with and treating #rarediseases, and evaluate the readiness of European #healthsystems to provide #access to cutting-edge #treatments for #patients. 🧬 This article, spearheaded by the Alliance for Regenerative Medicine (ARM) in partnership with the Thalassaemia International Federation - TIF and Fondazione Telethon, examines the crucial opportunity for the EU to develop a forward-looking framework that can realize the promise of #innovativetherapies for patients—a potential that must not be left untapped. https://lnkd.in/eSGdj-D4

A new study demonstrates the use of CAR-T cells to treat asthma, showing promising results. I believe the potential of CAR-T technology, especially when combined with iPSC-T cells and advanced engineering techniques, is endless and extends beyond oncological diseases. If such treatments could be achieved in human without immunodepletion, the impact would be even greater. #CAR-T #asthma https://lnkd.in/gzQuibJ7 https://lnkd.in/gGiBdyZK.